Jan Alenfall

Jan Alenfall holds a PhD and has over 20 years’ experience from pharmaceutical research and development, for example from research regarding new treatment for immunological diseases and cancer. Alenfall was Head of Pre-clinical and Clinical Development at Bioglan. He has also been Head of Research at Probi AB. Alenfall has solid experience within research, product development, pre-clinical and clinical trials and also in commercial collaborations. In 2006 he was appointed CEO at DermaGen AB. Alenfall has been the author and co-author of 17 publications in scientific journals and has six patent applications.